Adherence to Oral Anticancer Treatment Using Electronic Monitoring System

Inclusion Criteria: * Age \> 18 years * histologically proven malignant tumor * documented decision of treatment with i) a chemotherapeutic regimen with capecitabine (alone or in association with lapatinib), ii) or sunitinib an tyrosine kinase inhibitor, iii) or an non-steroidal aromatase inhibitor * ambulatory treated subject * Subject who accept to use MEMS monitors to automatically compile their drug dosing histories * Written informed consent Exclusion Criteria: * any severe concomitant wich makes it undesirable for the patient to participate in the study or which would jeopardize adherence with trial protocol * patient who does not agreed to participate the program